country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Art. -Nr.: HY-111145

Copy Link Print Information

RD162

Kundenbewertung

Based on 1 Customer Validation

RD162, a diarylthiohydantoin, is an orally active non-steroidal antiandrogen (NSAA). RD162 specifically binds to androgen receptor (AR). RD162 induces tumor regression in mouse models of castration-resistant human prostate cancer.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.69%
CAS. Nr.: 915087-27-3
Formel: C₂₂H₁₆F₄N₄O₂S
Molecular Weight:476.45

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

RD162 Chemical Structure

CAS. Nr.: 915087-27-3

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Lösungsmittel & Löslichkeit
- In Vitro
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Cellular Effect

Cell Line	Type	Value	Description	References
LNCaP	IC₅₀	122 nM Compound: 91	Inhibition of prostate specific antigen expression in human LNCAP cells in presence of fetal bovine serum Inhibition of prostate specific antigen expression in human LNCAP cells in presence of fetal bovine serum	[PMID: 20218717]

In Vitro

RD162 (1-10 μM; 4 days) suppresses growth and induces apoptosis in the human prostate cancer cell line VCaP which has endogenous AR gene amplification^[1].
RD162 has little to no binding to the progesterone, estrogen or glucocorticoid receptors in an in vitro fluorescence polarization assay^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

VCaP cells
Concentration:

1, 10 μM
Incubation Time:

4 days
Result:

Suppressed cell growth.

In Vivo

RD162 (10 mg/kg; oral gavage; daily; for 28 days) causes all tumors regressed^[1].
RD162 (0.1, 1, 10 mg/kg; oral gavage; daily; for 5 days) consistently reduces luciferase activity with 10 mg/kg/day human LNCaP/AR xenografts grown in castrated male mice whereas lower doses of 0.1 and 1.0 mg/kg/day has minimal effect. RD162 substantially reduces cellular proliferation after 5 days^[1].
RD162 (20 mg/kg; gavage) is ∼50 percent bioavailable after oral delivery with a serum half-life of about 30 hours^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Castrate male mice bearing LNCaP/AR xenografts^[1]
Dosage:

10 mg/kg
Administration:

Oral gavage; daily; for 28 days
Result:

Caused all tumors regressed.

Animal Model:

Male mice^[1]
Dosage:

20 mg/kg (Pharmacokinetic Analysis)
Administration:

Oral gavage (in 0.5% hydroxy-methyl-propyl-cellulose)
Result:

Had ∼50 percent bioavailable after oral delivery with a serum half-life of about 30 hours.

Chemical Information

CAS. Nr. 915087-27-3
Appearance Solid
Molecular Weight 476.45
Formel C₂₂H₁₆F₄N₄O₂S
Color White to off-white
SMILES

O=C(NC)C1=CC=C(N(C(N(C2=CC=C(C#N)C(C(F)(F)F)=C2)C3=O)=S)C43CCC4)C=C1F
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 125 mg/mL (262.36 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.0989 mL

10.4943 mL

20.9886 mL

5 mM

0.4198 mL

2.0989 mL

4.1977 mL

10 mM

0.2099 mL

1.0494 mL

2.0989 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (280 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Chris Tran, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009 May 8;324(5928):787-90. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.0989 mL	10.4943 mL	20.9886 mL	52.4714 mL
	5 mM	0.4198 mL	2.0989 mL	4.1977 mL	10.4943 mL
	10 mM	0.2099 mL	1.0494 mL	2.0989 mL	5.2471 mL
	15 mM	0.1399 mL	0.6996 mL	1.3992 mL	3.4981 mL
	20 mM	0.1049 mL	0.5247 mL	1.0494 mL	2.6236 mL
	25 mM	0.0840 mL	0.4198 mL	0.8395 mL	2.0989 mL
	30 mM	0.0700 mL	0.3498 mL	0.6996 mL	1.7490 mL
	40 mM	0.0525 mL	0.2624 mL	0.5247 mL	1.3118 mL
	50 mM	0.0420 mL	0.2099 mL	0.4198 mL	1.0494 mL
	60 mM	0.0350 mL	0.1749 mL	0.3498 mL	0.8745 mL
	80 mM	0.0262 mL	0.1312 mL	0.2624 mL	0.6559 mL
	100 mM	0.0210 mL	0.1049 mL	0.2099 mL	0.5247 mL

Keywords

MOQ

Minimum order quantity

100 mg

Angebot einholen Auf Lager

Other size

Angebot einholen

Amount: USD 0.00

Biologische Aktivität
- Beschreibung
- In Vitro
- In Vivo
Chemical Information
Lösungsmittel & Löslichkeit
- In Vitro
Reinheit & Dokumentation
Verweise

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

RD162

Orally Active Compound Library

Transcription Factor-Targeted Library

Anti-Prostate Cancer Compound Library

Nuclear Receptor Compound Library

Heterocyclic Compound Library

Highly Selective Inhibitors Library

Anti-Drug-Resistant Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Anti-Cancer Compound Library

Biologische Aktivität

Chemical Information

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

RD162

Orally Active Compound Library

Transcription Factor-Targeted Library

Anti-Prostate Cancer Compound Library

Nuclear Receptor Compound Library

Heterocyclic Compound Library

Highly Selective Inhibitors Library

Anti-Drug-Resistant Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Anti-Cancer Compound Library

Biologische Aktivität

Chemical Information

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

RD162 Related Classifications

HY-111145 Related Classifications